Skip to main content
. Author manuscript; available in PMC: 2023 Nov 3.
Published in final edited form as: Nature. 2023 May 3;617(7960):377–385. doi: 10.1038/s41586-023-06026-3

Extended Data Fig. 3. Combination therapy with anti-PD-1 or anti-PD-L1 plus anti-PD-L2 or anti-RGMb promotes an anti-tumor response in multiple, but not all, tumor types in SPF mice.

Extended Data Fig. 3.

MC38, B16-OVA, MB49, Py8119-OVA, LLC-OVA cells were implanted subcutaneously, and E0771 cells were injected into mammary fat pad of C57BL/6 mice with the indicated microbiota. The mice were treated with four doses of anti-PD-L1 or anti-PD-1 with/without anti-PD-L2 3.2 or anti-PD-L2 2C9 or anti-RGMb 9D1 one week after tumor implantation as indicated. (a) Growth of MB49 tumors in ABX mice given isotype, anti-PD-1 alone or combined with anti-PD-L2 3.2 n =10 mice per group for Isotype and anti-PD-1 + anti PD-L2 3.2 groups, n = 9 mice for anti-PD-1 group (b) Growth of MB49 tumors in ABX mice given isotype, anti-PD-L1 alone or combined anti-PD-L2 3.2 n = 10 mice per group (c) Growth of B16-OVA tumors in Taconic SPF mice given isotype, anti-PD-L1, anti-PD-L2 3.2 or anti-PD-L1 + anti-PD-L2. n= 5 mice per group for isotype and anti-PD-L2 3.2 groups and n= 10 mice per group for anti-PD-L1 and anti-PD-L1 + anti-PD-L2 3.2 groups. (d) Growth of Py8119-OVA in Taconic SPF mice given isotype or anti-PD-L1 and/or anti-PD-L2 3.2. n= 5 mice per group for all except n=4 mice for anti-PD-L2 3.2 group (e) Growth of MC38 tumors in Taconic SPF mice given isotype, anti-PD-L1, anti-PD-L2 3.2, or anti-PD-L1 + anti-PD-L2 n = 10 mice per group for all except n= 9 mice for anti-PD-L2 3.2 group. (f-g) Growth of E0771 tumors in Taconic SPF mice (f) given isotype, or anti-PD-1 combined with anti-PD-L2 3.2, anti-PD-L2 2C9 or anti-RGMb 9D1 n = 10 mice per group or (g) given isotype n=10 mice, anti-PD-L1 alone n= 9 mice or combined with anti-PD-L2 n=5 mice. (h) Growth of LLC-OVA tumors in Taconic SPF mice given isotype, anti-PD-L1, or anti-PD-L1 and either anti-PD-L2 3.2 or anti-RGMb 9D1. n=10 mice per group. Significance measured by two-way ANOVA and Tukey’s multiple comparisons test. Significant P vales are designated on graphs. Error bars show mean and s.e.m.